Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1169

—

d3ca041c-2bec-5a52-9665-befd0e6257c2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.428
  • MYC_TARGETS_V1+0.408
  • OXIDATIVE_PHOSPHORYLATION+0.407
  • INTERFERON_GAMMA_RESPONSE+0.285
  • PROTEIN_SECRETION+0.265
  • IL6_JAK_STAT3_SIGNALING+0.243
  • ANDROGEN_RESPONSE+0.238
  • KRAS_SIGNALING_UP+0.223
  • INFLAMMATORY_RESPONSE+0.210
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.143

Top 10 suppressed

  • ESTROGEN_RESPONSE_EARLY-0.278
  • MITOTIC_SPINDLE-0.257
  • CHOLESTEROL_HOMEOSTASIS-0.235
  • APICAL_JUNCTION-0.223
  • KRAS_SIGNALING_DN-0.212
  • HEDGEHOG_SIGNALING-0.211
  • ESTROGEN_RESPONSE_LATE-0.183
  • G2M_CHECKPOINT-0.154
  • WNT_BETA_CATENIN_SIGNALING-0.144
  • HEME_METABOLISM-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1f5174c29-918d-4ad9-bd44-c94463396414
colon-landscapes@1
——0.771
2SJEPD030097_D1.RNA-Seq
medullo-epn-umap@date-based
EPNMyxopapillary EPN0.758
3MNG632
mng-umap@100
——0.753
4MNG784
mng-umap@100
——0.747
5SRR8518236
breast-umap@18
—A0.745
610013d81-e167-4aa0-b548-5bb359ed403a
colon-landscapes@1
——0.741
7MNG67
mng-umap@100
——0.735
8ULC0563T_S23
lung-landscapes@6
—cohortMD20.726
9a3b44031-71ef-476f-a8bd-3694226ce026
colon-landscapes@1
——0.719
10BS_XF0ZX2B3
medullo-epn-umap@date-based
EPNSupratentorial EPN0.717

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.428Idelalisib— uncovered
MYC_TARGETS_V10.408Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.407Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.285Idelalisib— uncovered
PROTEIN_SECRETION0.265Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.243Inavolisib— uncovered
ANDROGEN_RESPONSE0.238Inavolisib— uncovered
KRAS_SIGNALING_UP0.223Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.210Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.143Inavolisib— uncovered
IL2_STAT5_SIGNALING0.143Idelalisib— uncovered
MTORC1_SIGNALING0.131Inavolisib— uncovered
COMPLEMENT0.117Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.115Idelalisib— uncovered
UV_RESPONSE_DN0.106Inavolisib— uncovered
PEROXISOME0.086Idelalisib— uncovered
ADIPOGENESIS0.085Inavolisib— uncovered
FATTY_ACID_METABOLISM0.080Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.065Inavolisib— uncovered
SPERMATOGENESIS0.065Inavolisib— uncovered